The invention relates to a quinoline of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2, which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkylamino or alkanoylamino each of up to 4 carbon atoms, or substituted alkyl or alkoxy each of up to 3 carbon atoms, provided that both R.sup.1 and R.sup.2 are not hydrogen; the quinoline ring may bear further substituents; R.sup.3 is hydrogen or alkyl of up to 4 carbon atoms; R.sup.4 is hydrogen, alkyl, alkenyl or alkynyl each of up to 4 carbon atoms or substituted alkyl of up to 3 carbon atoms; Ar is phenylene, naphthylene or heterocyclene which is unsubstituted or which bears one or more substituents; R.sup.5 is such that R.sup.5 --NH.sub.2 is an amino acid; or a pharmaceutically-acceptable salt or ester thereof. The compounds possess anti-tumor activity.
6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents
申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
公开号:EP0318225A2
公开(公告)日:1989-05-31
The invention relates to a quinoline of the formula:-
wherein each of R¹ and R², which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkylamino or alkanoylamino each of up to 4 carbon atoms, or substituted alkyl or alkoxy each of up to 3 carbon atoms, provided that both R¹ and R² are not hydrogen;
the quinoline ring may bear further substituents;
R³ is hydrogen or alkyl of up to 4 carbon atoms;
R⁴ is hydrogen, alkyl, alkenyl or alkynyl each of up to 4 carbon atoms or substituted alkyl of up to 3 carbon atoms;
Ar is phenylene, naphthylene or heterocyclene which is unsubstituted or which bears one or more substituents;
R⁵ is such that R⁵-NH₂ is an amino acid;
or a pharmaceutically-acceptable salt or ester thereof.
The compounds possess anti-tumour activity.
Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents
作者:Peter Warner、Andrew J. Barker、Ann L. Jackman、Kenneth D. Burrows、Neal Roberts、Joel A. M. Bishop、Brigid M. O'Connor、Leslie R. Hughes
DOI:10.1021/jm00093a007
日期:1992.7
synthase (TS) inhibitor N-[4-[N-[(2-amino-3,4-dihydro-4-oxo-6- quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamicacid (1, CB3717) have led to the synthesis of a series of quinoline antifolates bearing a variety of substituents at the C2 and C4 positions. In general the synthetic route involved the coupling of the appropriate diethyl N-[4-(prop-2-ynylamino)benzoyl]-L-glutamate with a disubstituted